2025 Q3 -tulosraportti
33 päivää sitten54 min
3,75 DKK/osake
Viimeisin osinko
3,90 %Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
714
Myynti
Määrä
586
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 214 | - | - | ||
| 4 | - | - | ||
| 214 | - | - | ||
| 70 | - | - | ||
| 10 | - | - |
Ylin
302,9VWAP
Alin
295,5VaihtoMäärä
781,3 2 620 248
VWAP
Ylin
302,9Alin
295,5VaihtoMäärä
781,3 2 620 248
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 36 247 | 36 247 | 0 | 36 247 |
| Danske Bank A/S | 5 472 | 5 472 | 0 | 5 472 |
| Nordea Bank Abp | 1 265 | 1 265 | 0 | 1 265 |
| Anonyymi | 2 746 941 | 2 746 941 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 36 247 | 36 247 | 0 | 36 247 |
| Danske Bank A/S | 5 472 | 5 472 | 0 | 5 472 |
| Nordea Bank Abp | 1 265 | 1 265 | 0 | 1 265 |
| Anonyymi | 2 746 941 | 2 746 941 | 0 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 4.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| Ylimääräinen yhtiökokous 2025 | 14.11. | |
| 2025 Q3 -tulosraportti | 6.11. | |
| 2025 Q3 -tulosraportti | 5.11. | |
| 2025 Q2 -tulosraportti | 7.8. | |
| 2025 Q2 -tulosraportti | 6.8. |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·47 min sittenBagsværd, Denmark and South San Francisco, CA, USA, December 9, 2025 – Novo Nordisk and Akero Therapeutics Inc. ("Akero") (Nasdaq: AKRO) today announced that Novo Nordisk's acquisition of Akero, announced on October 9, 2025, has been completed. With the completion of the transaction, Novo Nordisk has acquired all outstanding shares of Akero and equity equivalents thereof for 54 USD per share in cash (or a total value of 4.7 billion USD) as well as a non-transferable contingent value right ("CVR"). Each CVR entitles the holder to an additional payment of 6 USD per share in cash (or a total value of 0.5 billion USD) upon approval from U.S. authorities of Akero's leading drug candidate, EFX, for the treatment of compensated cirrhosis caused by MASH. Upon completion of the transaction, Akero became a wholly-owned subsidiary of Novo Nordisk. Akero's common shares will no longer be listed or traded on the Nasdaq Global Select Market. About the acquisition For more information about the acquisition, please see Novo Nordisk's company announcement here. About Akero Therapeutics Akero Therapeutics is a clinical-stage company developing transformative treatments for patients with serious metabolic diseases characterized by a significant unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Akero's leading product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, and SYNCHRONY Real-World in patients with MASH or MASLD (metabolic dysfunction-associated steatotic liver disease). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. Akero is headquartered in South San Francisco.- ·49 min sittenThe Novo Nordisk share could rise significantly in the next year. At least, that's according to French Kepler Cheuvreux, which is among the brokerage firms that see the greatest potential in the Danish pharmaceutical giant. The Novo Nordisk share has fallen significantly by about 70 pct. over the past year and a half, but the brokerage firm thus sees a possibility for the share to rise. The pharmaceutical giant's difficulties in defending its leading position against American Eli Lilly's weight loss drug Zepbound are fully reflected in the price, according to analyst David Evans via Marketwire. On the other hand, it is not factored into the Novo share price that Novo Nordisk is on its way with 'the first and best oral weight loss medicine', writes Marketwire based on the French brokerage firm, which refers to Wegovy in pill form and the next generation injection treatment, Cagrisema. Results from a study comparing Cagrisema with Zepound are expected to land in the first quarter. If Novo Nordisk's treatment shows better weight loss, it will likely drive the share price up, the analyst adds. Kepler Cheuvreux has a price target for the Novo share of 510 kr., according to data from the financial service Bloomberg. Based on the share's latest closing price of 299 kr. on Monday, this indicates a rise of a full 70 pct. Kepler Cheuvreux also has a buy recommendation for the share. A total of 17 out of the 33 analysts who cover the share according to Bloomberg do. 12 have a hold recommendation, while the last four recommend selling the share. https://www.euroinvestor.dk/nyheder/novo-aktien-rummer-markant-kurspotentiale-mener-boershus-saa-meget-kan-aktien-stige
·27 min sittenThat price target they have had since 22/8-2025 - so good luck with that 
·1 t sitten · MuokattuIf I were to make a guess about the red days. It's likely that several will sell parts or entire holdings of the stock until the FDA's decision is available. If the expectation is 5-8% up upon approval and 20% down in the opposite case. Then one can reasonably view it as risk management. So selling now and buying back after the decision could possibly be a strategy for some.
·1 t sitten · MuokattuThat Researchpulse1 account on X has provided interesting comments on IQVIA data for a couple of weeks now. https://x.com/ResearchPulse1/status/1998106192237736356 e.g.: Zepbound scripts declined 18.1% while Wegovy was down 12.5% w/w. Likewise Ozempic scripts fell 11.7% and Mounjaro was down 12.1% [..]it’s interesting that Ozempic and Mounjaro dropped more or less the same, while the difference was almost 6 percentage points between Zepbound and Wegovy. And from this post: https://x.com/ResearchPulse1/status/1995577884371796372 Interesting 99% of Zepbound sales growth in 2. Half 25 comes from vials…… so it’s cash pay that drives their whole growth. Which is weekly TRx 57.900 Just one week with new lower Wegovy prices made Wegovy gain significantly in Zepbound. Last weeks TRx for Wegovy is an increase of TRx 49,900 over last week in Q2 … That means Zepbound might not be such a popular and superior product after all. They have just been priced relatively similarly, and then people chose Zepbound because it's cash pay 💰 out of their own pocket, but now the prices for Wegovy have been drastically reduced. More than LLY has lowered the prices for Zepbound. So people suddenly have a dilemma. Starting Dec. 1, cash-paying patients with a valid prescription can pay $299 to $449 per month for Zepbound vials on LillyDirect, depending on the dose, down from a previous range of $349 to $499 per month. The prices for Wegovy have been reduced to $199 per month for beginner doses. That is $100 cheaper than Zepbound. For higher doses, it is now $349 per month, previously $499. Here, Wegovy and Zepbound follow each other, but Wegovy's prices have been lower since Nov. 17, where LLY only responded on Dec. 1. That is, after the Thanksgiving holiday in the USA. So, things are happening right now with new prescriptions in the USA. $199 for new Wegovy prescriptions versus $299 for Zepbound is a really good offer that LLY has chosen not to respond to. I think we will see Wegovy gain market share. Novo's offer on these intro doses for Wegovy is valid until March 31. That gives plenty of time to get a lot of new customers who have had time to eat during Christmas, think, and see a doctor in January. These customers must decide whether they want Wegovy or Zepbound. … Regardless of the price of the NVO stock right now, the strategy NVO has laid out will be very interesting to follow. I think it sounds really good in theory. I look forward to following it. We are probably looking at the big players pushing the price down as much as possible now, so they can buy cheaply as soon as good figures come out, or just before it turns around again.
·1 t sittenWhat has happened, was green this morning?😳 Anything new that has come?
·47 min sittenThe usual Novo Nordisk cannot maintain its current share price because they are not buying back their own shares and they haven't done that for a long time and that is the result look at the Danish stocks that buy back their own shares they support their stock and many of them even rise 🥳👌
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
33 päivää sitten54 min
3,75 DKK/osake
Viimeisin osinko
3,90 %Tuotto/v
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·47 min sittenBagsværd, Denmark and South San Francisco, CA, USA, December 9, 2025 – Novo Nordisk and Akero Therapeutics Inc. ("Akero") (Nasdaq: AKRO) today announced that Novo Nordisk's acquisition of Akero, announced on October 9, 2025, has been completed. With the completion of the transaction, Novo Nordisk has acquired all outstanding shares of Akero and equity equivalents thereof for 54 USD per share in cash (or a total value of 4.7 billion USD) as well as a non-transferable contingent value right ("CVR"). Each CVR entitles the holder to an additional payment of 6 USD per share in cash (or a total value of 0.5 billion USD) upon approval from U.S. authorities of Akero's leading drug candidate, EFX, for the treatment of compensated cirrhosis caused by MASH. Upon completion of the transaction, Akero became a wholly-owned subsidiary of Novo Nordisk. Akero's common shares will no longer be listed or traded on the Nasdaq Global Select Market. About the acquisition For more information about the acquisition, please see Novo Nordisk's company announcement here. About Akero Therapeutics Akero Therapeutics is a clinical-stage company developing transformative treatments for patients with serious metabolic diseases characterized by a significant unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Akero's leading product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, and SYNCHRONY Real-World in patients with MASH or MASLD (metabolic dysfunction-associated steatotic liver disease). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. Akero is headquartered in South San Francisco.
- ·49 min sittenThe Novo Nordisk share could rise significantly in the next year. At least, that's according to French Kepler Cheuvreux, which is among the brokerage firms that see the greatest potential in the Danish pharmaceutical giant. The Novo Nordisk share has fallen significantly by about 70 pct. over the past year and a half, but the brokerage firm thus sees a possibility for the share to rise. The pharmaceutical giant's difficulties in defending its leading position against American Eli Lilly's weight loss drug Zepbound are fully reflected in the price, according to analyst David Evans via Marketwire. On the other hand, it is not factored into the Novo share price that Novo Nordisk is on its way with 'the first and best oral weight loss medicine', writes Marketwire based on the French brokerage firm, which refers to Wegovy in pill form and the next generation injection treatment, Cagrisema. Results from a study comparing Cagrisema with Zepound are expected to land in the first quarter. If Novo Nordisk's treatment shows better weight loss, it will likely drive the share price up, the analyst adds. Kepler Cheuvreux has a price target for the Novo share of 510 kr., according to data from the financial service Bloomberg. Based on the share's latest closing price of 299 kr. on Monday, this indicates a rise of a full 70 pct. Kepler Cheuvreux also has a buy recommendation for the share. A total of 17 out of the 33 analysts who cover the share according to Bloomberg do. 12 have a hold recommendation, while the last four recommend selling the share. https://www.euroinvestor.dk/nyheder/novo-aktien-rummer-markant-kurspotentiale-mener-boershus-saa-meget-kan-aktien-stige·27 min sittenThat price target they have had since 22/8-2025 - so good luck with that
- ·1 t sitten · MuokattuIf I were to make a guess about the red days. It's likely that several will sell parts or entire holdings of the stock until the FDA's decision is available. If the expectation is 5-8% up upon approval and 20% down in the opposite case. Then one can reasonably view it as risk management. So selling now and buying back after the decision could possibly be a strategy for some.
- ·1 t sitten · MuokattuThat Researchpulse1 account on X has provided interesting comments on IQVIA data for a couple of weeks now. https://x.com/ResearchPulse1/status/1998106192237736356 e.g.: Zepbound scripts declined 18.1% while Wegovy was down 12.5% w/w. Likewise Ozempic scripts fell 11.7% and Mounjaro was down 12.1% [..]it’s interesting that Ozempic and Mounjaro dropped more or less the same, while the difference was almost 6 percentage points between Zepbound and Wegovy. And from this post: https://x.com/ResearchPulse1/status/1995577884371796372 Interesting 99% of Zepbound sales growth in 2. Half 25 comes from vials…… so it’s cash pay that drives their whole growth. Which is weekly TRx 57.900 Just one week with new lower Wegovy prices made Wegovy gain significantly in Zepbound. Last weeks TRx for Wegovy is an increase of TRx 49,900 over last week in Q2 … That means Zepbound might not be such a popular and superior product after all. They have just been priced relatively similarly, and then people chose Zepbound because it's cash pay 💰 out of their own pocket, but now the prices for Wegovy have been drastically reduced. More than LLY has lowered the prices for Zepbound. So people suddenly have a dilemma. Starting Dec. 1, cash-paying patients with a valid prescription can pay $299 to $449 per month for Zepbound vials on LillyDirect, depending on the dose, down from a previous range of $349 to $499 per month. The prices for Wegovy have been reduced to $199 per month for beginner doses. That is $100 cheaper than Zepbound. For higher doses, it is now $349 per month, previously $499. Here, Wegovy and Zepbound follow each other, but Wegovy's prices have been lower since Nov. 17, where LLY only responded on Dec. 1. That is, after the Thanksgiving holiday in the USA. So, things are happening right now with new prescriptions in the USA. $199 for new Wegovy prescriptions versus $299 for Zepbound is a really good offer that LLY has chosen not to respond to. I think we will see Wegovy gain market share. Novo's offer on these intro doses for Wegovy is valid until March 31. That gives plenty of time to get a lot of new customers who have had time to eat during Christmas, think, and see a doctor in January. These customers must decide whether they want Wegovy or Zepbound. … Regardless of the price of the NVO stock right now, the strategy NVO has laid out will be very interesting to follow. I think it sounds really good in theory. I look forward to following it. We are probably looking at the big players pushing the price down as much as possible now, so they can buy cheaply as soon as good figures come out, or just before it turns around again.
- ·1 t sittenWhat has happened, was green this morning?😳 Anything new that has come?·47 min sittenThe usual Novo Nordisk cannot maintain its current share price because they are not buying back their own shares and they haven't done that for a long time and that is the result look at the Danish stocks that buy back their own shares they support their stock and many of them even rise 🥳👌
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
714
Myynti
Määrä
586
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 214 | - | - | ||
| 4 | - | - | ||
| 214 | - | - | ||
| 70 | - | - | ||
| 10 | - | - |
Ylin
302,9VWAP
Alin
295,5VaihtoMäärä
781,3 2 620 248
VWAP
Ylin
302,9Alin
295,5VaihtoMäärä
781,3 2 620 248
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 36 247 | 36 247 | 0 | 36 247 |
| Danske Bank A/S | 5 472 | 5 472 | 0 | 5 472 |
| Nordea Bank Abp | 1 265 | 1 265 | 0 | 1 265 |
| Anonyymi | 2 746 941 | 2 746 941 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 36 247 | 36 247 | 0 | 36 247 |
| Danske Bank A/S | 5 472 | 5 472 | 0 | 5 472 |
| Nordea Bank Abp | 1 265 | 1 265 | 0 | 1 265 |
| Anonyymi | 2 746 941 | 2 746 941 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 4.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| Ylimääräinen yhtiökokous 2025 | 14.11. | |
| 2025 Q3 -tulosraportti | 6.11. | |
| 2025 Q3 -tulosraportti | 5.11. | |
| 2025 Q2 -tulosraportti | 7.8. | |
| 2025 Q2 -tulosraportti | 6.8. |
Datan lähde: FactSet, Quartr
2025 Q3 -tulosraportti
33 päivää sitten54 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 4.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| Ylimääräinen yhtiökokous 2025 | 14.11. | |
| 2025 Q3 -tulosraportti | 6.11. | |
| 2025 Q3 -tulosraportti | 5.11. | |
| 2025 Q2 -tulosraportti | 7.8. | |
| 2025 Q2 -tulosraportti | 6.8. |
Datan lähde: FactSet, Quartr
3,75 DKK/osake
Viimeisin osinko
3,90 %Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·47 min sittenBagsværd, Denmark and South San Francisco, CA, USA, December 9, 2025 – Novo Nordisk and Akero Therapeutics Inc. ("Akero") (Nasdaq: AKRO) today announced that Novo Nordisk's acquisition of Akero, announced on October 9, 2025, has been completed. With the completion of the transaction, Novo Nordisk has acquired all outstanding shares of Akero and equity equivalents thereof for 54 USD per share in cash (or a total value of 4.7 billion USD) as well as a non-transferable contingent value right ("CVR"). Each CVR entitles the holder to an additional payment of 6 USD per share in cash (or a total value of 0.5 billion USD) upon approval from U.S. authorities of Akero's leading drug candidate, EFX, for the treatment of compensated cirrhosis caused by MASH. Upon completion of the transaction, Akero became a wholly-owned subsidiary of Novo Nordisk. Akero's common shares will no longer be listed or traded on the Nasdaq Global Select Market. About the acquisition For more information about the acquisition, please see Novo Nordisk's company announcement here. About Akero Therapeutics Akero Therapeutics is a clinical-stage company developing transformative treatments for patients with serious metabolic diseases characterized by a significant unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Akero's leading product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, and SYNCHRONY Real-World in patients with MASH or MASLD (metabolic dysfunction-associated steatotic liver disease). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. Akero is headquartered in South San Francisco.
- ·49 min sittenThe Novo Nordisk share could rise significantly in the next year. At least, that's according to French Kepler Cheuvreux, which is among the brokerage firms that see the greatest potential in the Danish pharmaceutical giant. The Novo Nordisk share has fallen significantly by about 70 pct. over the past year and a half, but the brokerage firm thus sees a possibility for the share to rise. The pharmaceutical giant's difficulties in defending its leading position against American Eli Lilly's weight loss drug Zepbound are fully reflected in the price, according to analyst David Evans via Marketwire. On the other hand, it is not factored into the Novo share price that Novo Nordisk is on its way with 'the first and best oral weight loss medicine', writes Marketwire based on the French brokerage firm, which refers to Wegovy in pill form and the next generation injection treatment, Cagrisema. Results from a study comparing Cagrisema with Zepound are expected to land in the first quarter. If Novo Nordisk's treatment shows better weight loss, it will likely drive the share price up, the analyst adds. Kepler Cheuvreux has a price target for the Novo share of 510 kr., according to data from the financial service Bloomberg. Based on the share's latest closing price of 299 kr. on Monday, this indicates a rise of a full 70 pct. Kepler Cheuvreux also has a buy recommendation for the share. A total of 17 out of the 33 analysts who cover the share according to Bloomberg do. 12 have a hold recommendation, while the last four recommend selling the share. https://www.euroinvestor.dk/nyheder/novo-aktien-rummer-markant-kurspotentiale-mener-boershus-saa-meget-kan-aktien-stige·27 min sittenThat price target they have had since 22/8-2025 - so good luck with that
- ·1 t sitten · MuokattuIf I were to make a guess about the red days. It's likely that several will sell parts or entire holdings of the stock until the FDA's decision is available. If the expectation is 5-8% up upon approval and 20% down in the opposite case. Then one can reasonably view it as risk management. So selling now and buying back after the decision could possibly be a strategy for some.
- ·1 t sitten · MuokattuThat Researchpulse1 account on X has provided interesting comments on IQVIA data for a couple of weeks now. https://x.com/ResearchPulse1/status/1998106192237736356 e.g.: Zepbound scripts declined 18.1% while Wegovy was down 12.5% w/w. Likewise Ozempic scripts fell 11.7% and Mounjaro was down 12.1% [..]it’s interesting that Ozempic and Mounjaro dropped more or less the same, while the difference was almost 6 percentage points between Zepbound and Wegovy. And from this post: https://x.com/ResearchPulse1/status/1995577884371796372 Interesting 99% of Zepbound sales growth in 2. Half 25 comes from vials…… so it’s cash pay that drives their whole growth. Which is weekly TRx 57.900 Just one week with new lower Wegovy prices made Wegovy gain significantly in Zepbound. Last weeks TRx for Wegovy is an increase of TRx 49,900 over last week in Q2 … That means Zepbound might not be such a popular and superior product after all. They have just been priced relatively similarly, and then people chose Zepbound because it's cash pay 💰 out of their own pocket, but now the prices for Wegovy have been drastically reduced. More than LLY has lowered the prices for Zepbound. So people suddenly have a dilemma. Starting Dec. 1, cash-paying patients with a valid prescription can pay $299 to $449 per month for Zepbound vials on LillyDirect, depending on the dose, down from a previous range of $349 to $499 per month. The prices for Wegovy have been reduced to $199 per month for beginner doses. That is $100 cheaper than Zepbound. For higher doses, it is now $349 per month, previously $499. Here, Wegovy and Zepbound follow each other, but Wegovy's prices have been lower since Nov. 17, where LLY only responded on Dec. 1. That is, after the Thanksgiving holiday in the USA. So, things are happening right now with new prescriptions in the USA. $199 for new Wegovy prescriptions versus $299 for Zepbound is a really good offer that LLY has chosen not to respond to. I think we will see Wegovy gain market share. Novo's offer on these intro doses for Wegovy is valid until March 31. That gives plenty of time to get a lot of new customers who have had time to eat during Christmas, think, and see a doctor in January. These customers must decide whether they want Wegovy or Zepbound. … Regardless of the price of the NVO stock right now, the strategy NVO has laid out will be very interesting to follow. I think it sounds really good in theory. I look forward to following it. We are probably looking at the big players pushing the price down as much as possible now, so they can buy cheaply as soon as good figures come out, or just before it turns around again.
- ·1 t sittenWhat has happened, was green this morning?😳 Anything new that has come?·47 min sittenThe usual Novo Nordisk cannot maintain its current share price because they are not buying back their own shares and they haven't done that for a long time and that is the result look at the Danish stocks that buy back their own shares they support their stock and many of them even rise 🥳👌
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
714
Myynti
Määrä
586
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 214 | - | - | ||
| 4 | - | - | ||
| 214 | - | - | ||
| 70 | - | - | ||
| 10 | - | - |
Ylin
302,9VWAP
Alin
295,5VaihtoMäärä
781,3 2 620 248
VWAP
Ylin
302,9Alin
295,5VaihtoMäärä
781,3 2 620 248
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 36 247 | 36 247 | 0 | 36 247 |
| Danske Bank A/S | 5 472 | 5 472 | 0 | 5 472 |
| Nordea Bank Abp | 1 265 | 1 265 | 0 | 1 265 |
| Anonyymi | 2 746 941 | 2 746 941 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 36 247 | 36 247 | 0 | 36 247 |
| Danske Bank A/S | 5 472 | 5 472 | 0 | 5 472 |
| Nordea Bank Abp | 1 265 | 1 265 | 0 | 1 265 |
| Anonyymi | 2 746 941 | 2 746 941 | 0 | 0 |